Company / SG&A Expense
PULSE BIOSCIENCES, INC. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$32.0M
FY2025
5-year range
$14.0M / $32.0M
FY2021-FY2025
Trend
+33.9%
vs FY2024
Sector context
#153 of 158
Health Care
What the data says
Among 158 Health Care companies, PULSE BIOSCIENCES, INC. is in the top 3% for sg&a expense. SG&A Expense has fluctuated over the past 10 years, ranging from $3M in FY2016 to $32M in FY2025.
Based on SEC 10-K filings.
$32M in FY2025 with a 5-year CAGR of +14.5%.
Increased from $14M to $32M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +31.9%
- 5-Year CAGR
- +14.5%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 158This company $32.0M Sector average $175.9B
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +14.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 33.9% year-over-year.
- Ranks #153 out of 158 companies in the Health Care sector.
- Lowest sg&a expense in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.0M | +33.9% |
| FY2024 | $23.9M | +71.4% |
| FY2023 | $14.0M | +0.0% |
| FY2022 | $14.0M | -26.8% |
| FY2021 | $19.1M | +17.3% |
| FY2020 | $16.3M | -5.1% |
| FY2019 | $17.1M | -14.5% |
| FY2018 | $20.0M | +29.3% |
| FY2017 | $15.5M | +354.0% |
| FY2016 | $3.4M | +110.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026